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Objective. Drugs can induce almost the entire spectrum of hematologic disorders, aﬀecting white cells, red cells, platelets,
and the coagulation system. This paper aims to emphasize the broad range of drug-induced hematological syndromes and
to highlight some of the newer drugs and syndromes. Methods. Medline literature on drug-induced hematologic syndromes
was reviewed. Most reports and reviews focus on individual drugs or cytopenias. Results. Drug-induced syndromes include
hemolytic anemias, methemoglobinemia, red cell aplasia, sideroblastic anemia, megaloblastic anemia, polycythemia, aplastic
anemia, leukocytosis, neutropenia, eosinophilia, immune thrombocytopenia, microangiopathic syndromes, hypercoagulability,
hypoprothrombinemia, circulating anticoagulants, myelodysplasia, and acute leukemia. Some of the classic drugs known to cause
hematologic abnormalities have been replaced by newer drugs, including biologics, accompanied by their own syndromes and
unintended side eﬀects. Conclusions. Drugs can induce toxicities spanning many hematologic syndromes, mediated by a variety of
mechanisms. Physicians need to be alert to the potential for iatrogenic drug-induced hematologic complications.
Copyright © 2009 David M. Mintzer et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Hematological disorders arise through a variety of mecha-
nisms and etiologies. Drug-induced hematological disorders
can span almost the entire spectrum of hematology, aﬀecting
red cells, white cells, platelets, and the coagulation system.
Most recent reviews of drug-induced hematological disor-
ders focused on speciﬁc drugs or cytopenias. The purpose of
this review is to emphasize the broad range of drug-induced
hematologicalsyndromesandtohighlightsomeofthenewer
drugs and syndromes described. However, due to space
limitations, this review is not meant to be comprehensive of
all drug-induced hematological dyscrasias.
2. ImmuneHemolytic Anemia
Immune Hemolytic Anemia (IHA) is characterized by
destruction of red cells by antibodies acting against antigens
on the erythrocyte membrane. Mediated by either IgG or
IgM antibodies, IHA may be idiopathic, or secondary to
infections, autoimmune diseases, lymphoproliferative disor-
ders, or drugs. Patients present with anemia, reticulocytosis,
indirect hyperbilirubinemia, elevated LDH with a positive
Coombs test.
Drug-induced IHA may be associated with either drug-
dependent or drug-independent antibodies [1]. Other drugs
may cause nonimmunologic protein adsorption onto drug-
treated red cells. With drug independent autoantibodies,
typiﬁed by alpha-methyl DOPA, IHA can persist at length,
even after the drug is withdrawn. IHA has been described
withcephalosporins,nonsteroidal anti-inﬂammatoryagents,
levaquin, oxaliplatin, and teicoplanin, amongst others [1, 2].
Intravenous Rh(D) immune globulin, used for
treatment of immune thrombocytopenic purpura in
non-splenectomized Rh(D)-positive patients, intentionally
induces a mild hemolysis, which likely accounts for its
mechanism of action. However, severe hemolysis with renal
insuﬃciency, disseminated intravascular coagulation, and
death has been reported in a small number of cases [3].
Fludarabine, a purine nucleoside chemotherapeutic
agent, has been reported to precipitate or exacerbate the
auto-immune hemolytic anemia associated with chronic
lymphocytic leukemia. However, combining ﬂudarabine
with rituximab and cyclophosphamide may reduce that risk
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3. Nonimmune Hemolytic Anemias
G6PD deﬁciency is the most frequent red cell enzymopathy
associated with hemolysis. Hemolysis may be precipitated by
infection, fava beans, and drugs. The sensitivity to various
drugs depends on the inherited mutation and the associated
degree of deﬁciency. In most cases, drug-induced hemolysis
isself-limited.ThedeﬁciencyisX-linked,somanifestedmore
commonly and severely in males. Primaquine, phenazopyri-
dine, nitrofurantoin, and certain sulfas have been associated
with hemolysis [5].
Ribavirin, used with peginterferon for treatment of
hepatitis C, has been associated with anemia. Ribavirin
concentrates within red blood cells, depletes ATP, and
promotes hemolysis via oxidative membrane damage. While
the anemia will improve by stopping or dose-reducing
ribavirin, such strategies may compromise the eﬃcacy of
the antiviral therapy. Erythropoietin has been reported to be
helpful in moderating the anemia [6].
4. Methemoglobinemia
In approximately 3% of the body’s hemoglobin, the ferrous
iron in heme is oxidized upon deoxygenation, creating
methemoglobin. Most of this naturally occurring methe-
moglobin is reduced to hemoglobin through the methe-
moglobin reductase enzyme system. Methemoglobinemia,
characterized by excess production of methemoglobin,
causes impairment in the transport of oxygen. Methe-
moglobinemiacanbecongenital(duetodefectsinenzymatic
reduction of hemoglobin) or acquired. Patients present with
symptoms of anoxia, cyanosis, reduced oxygen saturation,
and chocolate-brown arterial blood. Conﬁrmation of the
diagnosis is made by measurement of methemoglobin on
arterial blood gas sampling.
Drugs that induce methemoglobinemia either directly
oxidize hemoglobin or are metabolically activated to an oxi-
dizingspecies[7].Phenazopyridine,usedforreliefofcystitis,
can cause oxidative hemolysis [8]. Dapsone, used for leprosy,
dermatitis herpetiformis, and prophylaxis for pneumocystis
carinii, is metabolized to a hydroxylamine derivative [9]. It
was the most common cause of methemoglobinemia in one
recent series [10]. Primaquine and local anesthetics, such as
topical or spray benzocaine (used prior to upper endoscopic
procedures) and prilocaine, can cause methemoglobinemia
[11–13]. Amyl nitrite and isobutyl nitrite have been impli-
cated also [7]. Treatment includes cessation of the inducing
agent, oxygen, and methylene blue.
5. Megaloblastic Anemia
Megaloblastic anemias are characterized by the presence
of a hypercellular bone marrow with large, abnormal
hematopoetic progenitor cells (megaloblasts). Leukopenia
and thrombocytopenia also occur. Megaloblastic anemias
can be congenital or acquired and most commonly are
relatedtovitaminB12 (cobalamin)andfolicaciddeﬁciencies.
While they are usually a result of malnutrition or defective
absorption, they can also be drug-induced.
Drugs that act by interfering with DNA synthesis, such as
antimetabolites and alkylating agents, some antinucleosides
used against HIV and other viruses [14], can all induce
megaloblastic anemia. Trimethoprim (in high, extended
doses) and pyrimethamine, which bind with greater aﬃnity
to bacterial than human dihydrofolate reductase, have been
associated with megaloblastic anemia, primarily among
patients already at risk for folic acid deﬁciency. Antibiotics
such as sulfasalazine and anticonvulsants such as phenytoin
have been linked to folate-related changes which induce
megaloblastic anemia, perhaps related to interference with
absorption.
Decreasedcobalaminlevelshavebeenreportedwithterm
use of histamine 2-receptor antagonists and proton pump
inhibitors (e.g., omeprazole) [15, 16]. While protein bound
B12 absorption may be impaired by these agents, clinically
signiﬁcant B12 deﬁciency seems rare despite widespread use.
6. Sideroblastic Anemia
Sideroblastic anemias (SAs) are characterized by ringed
sideroblasts (erythroblasts containing iron-positive gran-
ules arranged around the nucleus) in the bone marrow.
Sideroblastic anemias, which can be inherited or acquired,
exhibit impaired heme biosynthesis inerythroid progenitors.
Most sideroblastic anemias are acquired as clonal disorders
of erythropoiesis. Additionally, ringed sideroblasts can be
found in malnourished patients who abuse alcohol [17].
Drug-induced sideroblastic anemia has been associated
with isoniazid [18]. The anemia is reversed by pyroxidine or
by withdrawal of isoniazid. Chloramphenicol, rarely used at
present, causes a reversible suppression of erythropoiesis and
produces ringed sideroblasts [17]. Linezolide, penicillamine,
and triethylene tetramine dihydrochloride (a chelating agent
used to treat Wilson’s disease) induce reversible SA [19–
21]. Myelodysplasias and secondary acute leukemias induced
by chemotherapy, discussed below, may initially manifest as
sideroblastic anemia [22].
7. Aplastic Anemia
Aplastic anemia (AA), characterized by pancytopenia with
a hypocellular bone marrow, can be inherited or acquired.
Acquired aplastic anemia is most commonly idiopathic, but
may be secondary to exposure to toxins, irradiation, viruses,
and drugs. AA can develop as a direct response to exposure,
but can also develop indirectly, through immune-mediated
mechanisms. Historically, drug-induced AA has not been
easily distinguished from idiopathic forms of the disease
since with rare case reports causality is diﬃcult to establish
[23]. From an immunological perspective, the absence of
antibodiesinaplasticanemiasuggeststhatdrugsdonotserve
as simple haptens in the initiation of aplastic marrow failure.
Drugs implicated in inducing AA include antirheumatic
drugs, antithyroid medications, antituberculous drugs,
NSAIDs, and anticonvulsants. Speciﬁc drugs cited includeAdvances in Hematology 3
chloramphenicol, butazone, sulfonamide, gold salts, peni-
cillamine, amidopyrine, trimethoprim/sulfamethoxazole,
methimazole, and felbamate [24–27].
Many drugs reported to cause aplastic anemia can also
more commonly cause mild marrow suppression, suggesting
that preliminary damage may occasionally (perhaps related
to host metabolism) progress to more severe damage. The
treatment and prognosis of drug-induced aplastic anemia
seem similar to idiopathic cases [23].
8.PureRedCellAplasia
Pure red cell aplasia (PRCA) is characterized by normocytic
anemia, reticulocytopenia, and absence of mature marrow
erythroid progenitors. PRCA is distinguished from aplastic
anemia by relatively normal leukocyte and platelet counts.
It can be congenital or acquired. Acquired PRCA can
be idiopathic or secondary, either an acute, self-limiting
disorder or a persistent, chronic refractory anemia. PRCA
can arise in association with a thymoma, lymphoid cancer,
parvovirus, rheumatoid arthritis, pregnancy, and drugs.
PRCA can be acquired through exposure to a number of
drugs,includingimmunosuppressants(azathioprine,FK506,
antithymocyte globulin), antibacterials (linezolide, isoni-
azid, rifampin, chloramphenicol), antivirals (interferon-
alpha,lamivudine,zidovudine),ﬂudarabine,anticonvulsants
(diphenyldrantoin, carbamazepine, valporic acid), as well as
chloroquine, allopurinol, ribavirin, and gold [28, 29].
Additionally, PRCA has been reported to develop after
prolonged exposure to recombinant human erythropoietin
(rHuEPO) speciﬁcally the brand Eprex, predominately used
in Europe [30–33]. Withdrawal of rHuEPO followed by
treatment with immunosuppressives (cyclosporine A) for
several months rendered patients anti-EPO antibody nega-
tive and transfusion independent. PRCA seemed to occur
predominantly with subcutaneous administration in renal
failure patients. The frequency of this complication has
reduced, seemingly as a result of changes in formulation and
handling that may have decreased immunogenicity [33].
9. ImmuneThrombocytopenia
In immune thrombocytopenia purpura (ITP), platelet
destruction is caused as antibodies bind to platelets leading
to their clearance by the reticuloendothelial system (RES),
as well as by some degree of decreased production. ITP can
be idiopathic, or related to viral infections, autoimmune
disorders, lymphoproliferative disorders, or drugs [34, 35].
Classical causes of drug-induced thrombocytopenia are
the quinine and quinine-like drugs [36]. The thrombocy-
topenia is typically sudden, severe, and may be accompanied
by bleeding. The thrombocytopenia induced by these drugs
is caused by antibody that is nonreactive in the absence
of drug, but binds to epitopes on platelet membrane,
glycoproteins IIb/IIIa or Ib/IX, when the sensitizing drug
is present. Vancomycin can also be associated with marked
thrombocytopenia and demonstrable drug-dependent anti-
bodies in the serum [37]. Prolonged thrombocytopenia may
occur in patients with renal insuﬃciency, likely due to
delayeddrugclearance.Otherdrugsassociatedwithimmune
thrombocytopenia include include antimicrobials (sulfano-
mides, rifampin, linezolid), anti-inﬂammatory drugs, anti-
neoplastics, antidepressants, benzodiazepines, anticonvul-
sants (carbamazepine, phenytoin, valproic acid) as well as
cardiac and antihypertensive drugs [34, 35]. Although the
ITP generally develops rapidly, it usually resolves upon
cessation of treatment and is drug-speciﬁc.
Heparin is well known to be associated with thrombo-
cytopenia, sometimes with arterial or venous thrombosis,
whichisgenerallyafargreaterthreatthantheriskofbleeding
[38, 39]. Heparin-induced immune thrombocytopenia is
caused by antibodies against complex of heparin and platelet
factor 4 (PF4), which can lead to platelet activation and the
initiation of thromboses. Although heparin can also induce
a milder, nonimmune mediated thrombocytopenia, the
immune version is potentially more severe. Heparin-induced
thrombocytopenia follows exposure to both unfractionated
and low molecular weight heparins, but is less common
with the latter. There is usually a delay of 5–10 days for
newly exposed patients, but thrombocytopenia can occur
within hours in patients with a recent heparin exposure
who still have PF4 antibodies, or within a few days for
those with prior exposure who develop an anamnestic
response. Occasionally venous gangrene, skin necrosis, and
acute anaphylactic-type reactions to heparin can occur. In
the appropriate clinical setting, the diagnosis is supported by
evidence of antiheparin antibodies, which can be detected
by a number of assays. These include the more sensitive
serologic assays (e.g., by ELISA) and the functional, more
speciﬁc assays such as measuring C-14 serotonin platelet
release in the presence of heparin and serum. In addition to
cessation of heparin use, treatment involves anticoagulation
to reduce the risk of thrombosis, typically with argatroban,
bivalrudin, or lepirudin initially, with transition to warfarin.
Anticoagulation should be continued for several weeks even
after the platelet count returns to normal due to the high risk
of thrombosis during that time.
Abciximab (a chimeric Fab fragment) and eptiﬁbatide
and tiroﬁban (ligand mimetic inhibitors) are frequently used
following coronary angioplasty to reduce thrombosis by
impairing platelet function through the inhibition of GP
IIb/IIIa-ﬁbrinogen interaction. In addition to inducing the
desired platelet dysfunction, however, they can induce a
severe thrombocytopenia in a small percentage of patients,
likelythroughadrug-dependentantibody-mediatedmecha-
nism [40]. This may begin within hours to days and typically
resolves spontaneously in 2–5 days. It may occur on the
initial or subsequent infusions. The majority of patients
recover without complications though severe bleeding may
occasionally occur. Platelet transfusions can be given if there
is signiﬁcant bleeding.
10.Thrombotic Microangiopathies
Thromboticmicroangiopathies(TMAs)presentwiththrom-
bocytopenia, microangiopathic hemolytic anemia, and4 Advances in Hematology
symptoms of microvascular occlusion. They arise from
excess platelet aggregation. TMA has often been associ-
ated with low levels of metalloprotease ADAMTS13, which
induces cleavage of von Willebrand factor (vWF). Throm-
botic thrombocytopenic purpura (TTP) and hemolytic-
uremic syndrome (HUS) are the main thrombotic microan-
giopathies. TMA can be familial, idiopathic or acquired
secondary to toxins, pregnancy, infections (e.g., HIV, certain
Shigella and E. coli), and drugs.
Although drug-induced TMA is well-documented, its
mechanism is not well-determined [41–44]. Immune-
mediated or direct toxicity factors are most often proposed.
In some patients with drug-induced TMA, autoantibodies to
the ADAMTS13 protease are present, in some patients TMA
incidence seems to be dose-dependent, and in many cases,
there are no “hints” of mechanism at all.
One drug commonly implicated in inducing TMA is
theimmunosuppressantcyclosporineA(CyA).CyA-induced
TMAisseenoftenintransplantpatients(solidorliquid),but
also in patients treated for rheumatoid arthritis and uveitis.
The mechanism is believed to be a dose-related toxicity.
TMA generally resolves once CyA treatment is reduced or
discontinued.
Other drugs associated with TMA include chemother-
apeutic agents mitomycin-C, gemcitabine, and cisplatin, as
well as α-interferon and tacrolimus [41–43]. In patients with
metastatic adenocarcinoma, it may be diﬃcult to distinguish
drug-induced TMA from anemia, thrombocytopenia, and
microangiopathy related to carcinomatosis. Mitomycin-C
is a known nephrotoxin, and there is evidence that its
mechanism for inducing TMA is a dose-dependent, direct
toxic eﬀect on endothelium.
The thienopyridines, antiaggregating agents ticlopidine,
and less commonly clopidogrel, have also been implicated in
inducingTMA[44].Ticlopidine-relatedTPAismorelikelyto
occurafteratleasttwoweeksoftherapy,tobeassociatedwith
low ADAMTS13 levels with demonstrable auto-antibodies,
and to beneﬁt from plasma exchange therapy. Clopidogrel-
induced TMA tends to occur within the ﬁrst two weeks of
treatment, is less likely to be associated with low ADAMTS13
levels and auto-antibodies, and is less likely to beneﬁt from
plasma exchange.
Quinine may also induce TMA. The mechanism is
immune-mediated. Patients with quinine-induced TMA
have been found with antibodies against endothelial cells,
lymphocytes, and granulocytes as well as quinine-dependent
antibodies including IgG or IgM reactive with platelet
glycoprotein Ib/IX or IIb/IIIa. TMA generally resolves with
withdrawal of quinine along with plasma exchange [45].
11.PlateletDysfunction
Disorders of platelet function may be detected in patients
with prolonged bleeding times but normal platelet counts.
While inducing platelet dysfunction to reduce the risk of
thrombosis is often the desired purpose of some drugs (such
as aspirin, clopidogrel, and anti-GP IIb/IIIa inhibitors), it
may also be an undesired side eﬀect [46].
Acetylation of cyclooxygenase 1 (COX 1) leads to
impaired synthesis of the important platelet agonist throm-
boxane A2. Aspirin irreversibly acetylates COX 1, so that its
eﬀectpersistsevenafterthedrugceasestocirculate.Thisisin
contrast with nonselective nonsteroidal anti-inﬂammatory
drugs, which reversibly acetylate COX 1. There is some
evidence that aspirin has a dose-related eﬀect on platelet
aggregation [47].
Fluoxetine and some tricyclic antidepressants, induce
dysfunction by inhibiting serotonin uptake. Certain drugs
can interfere with platelet adhesion or aggregation, includ-
ing high dose pencillins and other β-lactam antibiotics,
chemotherapy drugs such as mithramycin and daunoru-
bicin, immunosuppresants, and phenothiazines [46].
12.Hypercoagulability
Hypercoagulability, with a propensity to both arterial and
venous thrombosis, can be inherited or acquired. Hereditary
thrombophilic conditions include factor V Leiden, pro-
thrombin G20210A mutation, and deﬁciencies of proteinsC,
S or antithrombin III, among others. Acquired hypercoagu-
lable states can be secondary to immobility, surgery, trauma,
pregnancy, antiphospholipid syndrome, cancer, and drugs.
Selective COX-2 inhibitors, with less potential for
bleeding and gastrointestinal toxicity than traditional COX
inhibitors, became widely utilized as analgesics and anti-
inﬂammatory agents and were also investigated for their
potential eﬀect of reducing the risk of polyps and colorectal
cancer. However, celecoxib, rofecoxib, and valdecoxib were
found to be associated with increased thrombotic cardio-
vascular events in several trials [48–50]. These results led
to a voluntary withdrawal of rofecoxib from the worldwide
market and focused intense scrutiny on pharmaceutical and
FDA policies.
Erythropoietin has been associated with increased
thrombotic risk. While erythropoietin markedly beneﬁts the
anemia of renal failure, targeting hemogloblin levels to high
normal, it has been associated with higher cardiovascular
morbidity and mortality than with lower target levels
[51]. Questions have also been raised about the safety of
erythropoietin in cancer patients. A meta-analysis did show
increased thrombotic risk in treated patients, with some
studies showing an increased risk of death [52]. Guidelines
for more restricted and safer use of these agents in cancer
patients are undergoing modiﬁcation.
Hormonal therapies including oral contraceptives, hor-
mone replacement therapy, and tamoxifen (a selective estro-
gen receptor modulator with some agonist activity) have
all been associated with increased thrombotic risk. With
oral contraceptives, risk of arterial and venous thrombosis
may increase with age, genetic thrombophilias, smoking,
and use of certain types of associated progestin [53].
The Women’s Health Initiative study found that use of
combined estrogen and progestin doubled the risk of
venous thrombosis compared to placebo control [54]. For
chemoprevention of breast cancer, raloxifene was found to
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tamoxifen, and thus may be a safer drug in this setting [55].
Likewise, aromatase inhibitors such as anastrazole, letrozole,
or exemestane used for treatment for early or advanced
breast cancer demonstrate a lower thrombotic risk than
tamoxifen [56].
Adjuvant chemotherapy for breast cancer with CMF
(cyclophosphamide, methotrexate, ﬂuorouracil), an older
regimen infrequently used presently, was associated with
hypercoagulability [57–59]. Patients treated with CMF may
have reduced levels of the inhibitors proteins C and S
[57]. Thrombosis in patients receiving adjuvant chemother-
apy may have become less common in part because of
changes in types of chemotherapy used, a shorter duration
of chemotherapy, the less frequent use of tamoxifen in
postmenopausal patients, and the less frequent use of
concomitant (as opposed to sequential) chemotherapy and
tamoxifen [58].
Thrombotic complications have been associated with
asparaginase, used to treat acute lymphoblastic leukemia
[60–62]. Arterial and venous thromboses (including cerebral
venous sinuses) can occur. L-asparaginase inhibits protein
synthesis through the hydrolysis of the essential amino
acid asparagine, causes reduced synthesis of antithrombin
III, protein C, and protein S, thus leads to the increased
thrombotic risk.
Thalidomide and lenalidomide, used for multiple
myeloma, have been associated with increased thrombotic
risk when used in combination with glucocorticoids [63].
Various prophylactic measures including warfarin, heparin,
and aspirin have been recommended. The use of a less
intensiveonce-weeklydexamethasonescheduledecreasesthe
thrombotic risk in comparison with the standard 4-day high
dose schedule in combination with lenalidomide [63].
Drug-induced thrombosis from warfarin or heparin can
be associated with skin necrosis. Warfarin-induced skin
necrosis is often associated with preexisting thrombophilic
conditions, such as protein C, S, or antithrombin III deﬁ-
ciency [64]. Therapy consists of discontinuation of warfarin,
administration of vitamin K, and anticoagulation with hep-
arin. However, heparin can also induce skin necrosis which
may be part of the heparin-induced thrombocytopenia
syndrome [65].
Bevacizumab, a monoclonal antibody against vascular
endothelial growth factor, is used in metastatic colon, lung,
andbreastcancershasbeenassociatedwithincreasedarterial
thrombotic risk, particularly in elderly persons already
predisposed to cardiovascular events [66].
13.CirculatingAnticoagulants
Circulating anticoagulants inhibit clotting factors, caus-
ing excess hemorrhage. Autoantibodies such as acquired
inhibitors to factor VIII may be idiopathic or secondary to
hereditary hemophilia, the postpartum state, other autoim-
mune disorders, malignancies, or drugs. Patients present
with bleeding as a syndrome of acquired hemophilia, with
lowFVIII:clevelsanddemonstrableFVIIIinhibitors.Drugs
implicated include antibiotics, psychotropics, ﬂudarabine,
and interferon [67]. Antibody activity resolves with cessation
of the drug or with the use of immunosuppressive agents.
An acquired inhibitor to factor XIII, which cross-links and
stabilizes ﬁbrin, has been associated with isoniazid [68].
Lupus anticoagulants and antiphospholipid antibod-
ies may be induced by drugs such as chlorpromazine,
hydralazine, phenytoin, quinine, and procainamide [69, 70].
In these cases, there is an association with hypercoagulability
as opposed to bleeding.
14. Hypoprothrombinemia
Hypoprothombinemia, with prolongation of the PT/INR,
is most commonly due to vitamin K deﬁciency or liver
disease. Certain drugs have been linked with hypopro-
thrombinemia, such as broad spectrum antibiotics, usu-
ally in patients who are also malnourished. Reports have
linked sulfonamides, ampicillin, chloramphenicol, tetracy-
clines, and cefoxitin to deﬁciency in vitamin K-dependent
clotting factors [71]. Cephalosporins may be associated
with hypoprothrombinemia, especially those with the N-
methyl-thiotetrazole (NMTT) side chain (e.g., moxalactam,
cefoperazone), although these are no longer in common use
[72].
For patients on warfarin, many drugs, especially antibi-
otics, are associated with increased hemorrhage. It is noted
that there has been little systematic work on this subject,
with the main sources being case reports [73]. Nonetheless,
it is clear that many drugs interfere with coumadin through
alteration of pharmacokinetics or dynamics (e.g., antibiotics,
particularly quinolones, macrolides, and azoles), while oth-
ers add to bleeding risk by their own mechanisms (e.g.,
aspirin, heparin, ticlopidine, and NSAIDs). Careful moni-
toring and dose adjustments are necessary when prescribing
those medications to patients on warfarin.
15.Agranulocytosis/Neutropenia
Drug-induced neutropenia can occur in association with
various analgesics, psychotropics, anticonvulsants, antithy-
roid drugs, antihistaminics, antirheumatics, GI drugs,
antimicrobials, cardiovascular drugs, and, as expected, with
chemotherapy drugs. [74–76]. Immune-mediated mecha-
nisms are associated with some drugs such as penicillins
which act as a haptens inducing antibody formation against
neutrophils. Clozapine accelerates apoptosis of neutrophils,
and propythiouracil causes complement mediated destruc-
tion of neutrophils. Drugs such as β-lactam antibiotics, car-
bamazepine,andvalproatehaveadose-dependentinhibition
of granulopoiesis. Drugs with direct toxic eﬀects on myeloid
precursors include ticlopidine, bulsufan, methamizole, etho-
suximide, and chlorpromazine.
Treatment of drug-induced neutropenia includes with-
drawing the drug, antibiotic coverage when appropriate,
and increasingly administration of recombinant human
granulocytecolony-stimulatingfactor(rhG-CSF).Theuseof
CSFs can reduce the duration of neutropenia, the frequency
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with profound neutropenia [76]. Mortality, although lower
than in the past, remains about 5%.
Rituximab, an anti-CD20 antibody, used in the treat-
ment of B cell lymphoproliferative disorders and in benign
autoimmune disorders, can induce neutropenia, typically of
delayed-onset [77].
16. Neutrophilia
Neutrophilia can be related to myeloproliferative disorders
but more commonly results from infection or inﬂammation.
Drugs can also induce leukocytosis. Glucocorticoids cause
neutrophilia by inducing the release of neutrophils from
the bone marrow [78]. Although variable, glucocorticoids
typically do not cause leukocytosis over 20000/uL or a left
shift. Such an elevation in WBC counts, or an increase
in bands, might suggest the presence of infection [79].
Adrenergic-agonists and epinephrine produce neutrophilia
by releasing neutrophils from the marginated pool [78].
Lithium causes mild neutrophilia and was used as treatment
for neutropenia prior to the availability of CSFs [80].
Leukocytosis is commonly seen with G/GM-CSF, fre-
quently given to reduce the severity and duration of
neutropenia from chemotherapy. Sweet’s Syndrome (acute
febrile neutrophilic dermatosis), characterized by tender
erythematous skin lesions, fever, and neutrophilia, can be
induced by drugs such as trimethoprim-sulfamethoxazole,
other antibiotics, and granulocyte colony stimulating factor,
amongst others [81]. The syndrome can also be idiopathic or
paraneoplastic.
17.Eosinophilia
Eosinophilia can result from both intrinsic hematologic
disorders as well as secondary to a variety of systemic
disorders and allergens, including drugs [82]. Drugs most
commonly associated have included penicillins, sulfas, allop-
urinol, phenytoin, carbamazepine, and gold. Drug Rash with
Eosinophilia and Systemic Symptoms (DRESS syndrome)
describes the association of eosinophilia with rash, fever, and
visceral involvement, such as pneumonitis, hepatitis, nephri-
tis, adenopathy, or carditis [83]. DRESS has been associated
most commonly with antibiotics, and anticonvulsants, but
other agents have also been implicated.
18. Polycythemia
Polycythemia may be primary (polycythemia vera) or sec-
ondary to smoking, chronic hypoxia, certain tumors, or
drugs. Drug-induced polycythemia can be seen with excess
use of rHuEPO or anabolic steroids. Abuse of both types of
agents by athletes may be associated with increased throm-
botic risk [84]. Use of diuretics with volume contraction can
contribute to pseudopolycythemia, where the hematocrit is
elevated from hemoconcentration but true red cell mass is
not increased.
19.MyelodysplasiaandAcute Leukemia
Myelodysplastic syndromes (MDSs) and acute myeloid
leukemia (AML) are clonal hematopoietic disorders asso-
ciated with cytopenias, defective marrow maturation, and,
ultimately, unregulated blast proliferation. Many cases of
MDS evolve into AML, and although the two diseases are
distinct, they share a continuous spectrum.
The majority of MDS and AML cases are idiopathic,
but exposure to toxins and radiation can increase risk.
Drugs can also induce MDS [85, 86]. Alkylating agents
(such as nitrogen mustard, cyclophosphamide, melphalan,
busuﬂan, chlorambucil) are the most frequently cited per-
petrators. Risk has been related to total dose, duration,
and speciﬁc type of alkylating agent. Procarbazine and
nitrosoureas are also associated with myelodysplasia and
leukemia. There can be a latent period of 2–8 years prior
to development of t-MDS or AML. Leukemia induced by
these agents is commonly preceded by a myelodysplastic
syndrome. These leukemias are typically FAB M1 or M2
morphologically. Complex chromosomal abnormalities are
typical, commonly with deletions of chromosome 5 and 7
and trisomy 8.
A distinct syndrome of secondary leukemia is related to
topoisomeraseIIinhibitors,whichincludestheepipodophyl-
lotoxins (etoposide and teniposide), anthracyclines (dauno-
mycin, epirubicin, and doxorubicin.), and mitoxantrone.
Leukemia with these agents has a shorter latency period than
that associated with alkylating agents, often less than 2 years
and usually presents without a prior MDS. Morphologically,
acute myelomonocytic leukemias with a karyotypic abnor-
mality involving 11q23 are commonly seen.
Treatment-related acute promyelocytic leukemia has also
been described, most commonly in association with topo II
inhibitors[87].Thesealsohavearelativelyshortlatencyfrom
treatment without a preceding preleukemic phase. Like de
novo APL, t (15;17) with PML-RAR alpha rearrangements
are common. Treatment outcomes are relatively favorable
when treated like de novo APL, unlike the poor prognosis
seen in other t-AML types.
In patients receiving adjuvant chemotherapy for breast
cancer, the risk of acute leukemia increases with age, with the
intensity of therapy, and with the use of breast radiotherapy
[88]. Many of these patients have received both alkylating
agents and anthracyclines, both of which are leukemogenic.
In addition, an increased risk of AML has been noted
in breast cancer patients who received G-CSF along with
adjuvant chemotherapy in some [89] but not all studies [90].
Stem cell transplantation, used in high risk, relapsed,
and refractory hematologic malignancies, is associated with
a risk of secondary MDS and leukemia. Whether the disease
is induced by pretransplant therapy or the transplant itself
remains uncertain.
Radioimmunotherapy, developed for non-Hodgkins
lymphoma, may be associated with some risk of leuke-
mogenesis. However, as with transplant patients, some of
the risk may be related to stem cell damage from prior
treatments or perhaps an increased risk related to the
underlying disease itself. Small numbers of patients treatedAdvances in Hematology 7
Table 1: Drug induced hematologic syndromes.
Syndrome Examples of associated drugs References
Immunohemolytic
anemia
Pencillins, cephaloporins,
alpha-methyl-DOPA, oxaliplatin,
ﬂudarabine, anti-Rh D
antiglobulin
[1–4]
Nonimmune hemolytic
anemia
Ribavirin, phenazopyridine,
chloroquine, [5, 6]
Methhemoglobinemia Phenazopyridine, dapsone,
benzocaine, prilocaine [7–13]
Megaloblastic anemia Rrimethoprim, pyrimethamine,
diphenyhydantoin [14–16]
Sideroblastic anemia Isoniazid, chloramphenicol,
linezolide [17–22]
Aplastic anemia Chloramphenical, gold, NSAIDs, [23–27]
Pure red cell aplasia
Diphenylhydantoin,
azathioprine, chlopropamide,
isoniazid, erythropoietin
[28–33]
Immune
thrombocytopenia
Quinine, quinidine, heparin,
vancomycin, sulfas, pencillins,
glycoprotein IIb-IIIa inhibitors
[34–40]
Thrombotic
microangiopathy
Quinine, quinidine, clopidogrel,
ticlopidine, cylosporine A,
mitomycin-C, cisplatin
[41–45]
Platelet dysfunction Pencillins, beta-lactam
antibiotics, aspirin, NSAIDs [46, 47]
Hypercoagulability
Estrogens, tamoxifen,
asparaginase, heparin,
bevacizumab,
thalidomide/lenalidomide,
COX-2 inhibitors, erythropoietin
[48–66]
Circulating
anticoagulants
Isoniazid, hydralazine,
procainamide [67–70]
Hypoprothrombinemia Cephalosporins, pencillins, sulfas [71–73]
Neutropenia
Antithyroid drugs,
procainamide, sulfas, captopril,
phenothiazines,
diphenylhydantoin, rituximab
[74–77]
Neutrophilia Glucocorticoids, lithium, G- and
GM-CSF [78–81]
Eosinophilia Pencillins, sulfas, allopurinol,
diphenylhydantoin [82, 83]
Polycythemia Erythropoietin, anabolic
steroids, diuretics [84]
Acute
leukemia/myelodyplasia
Alkylating agents, topoisomerase
II inhibitors [85–95]
with radioimmunotherapy alone have shown a seemingly
low risk for leukemia [93].
20. Conclusions
The wide spectrum of drug-induced hematologic syndromes
is mediated by a variety of mechanisms, including immune
eﬀects, interactions with enzymatic pathways, and direct
inhibition of hematopoiesis. The table summarizes the
drug-induced hematological syndromes discussed above.
Providing proof that a drug causes a particular hematologic
syndromeisfrequentlyimpossible.Manypatientssimultane-
ously receive multiple drugs, making it diﬃcult to be certain
of causality. Rechallenge with a drug suspected of causing
toxicity is usually not advisable. For some drugs, such as
heparin, quinidine, and vancomyin, in vitro testing has
been performed and mechanisms for cytopenias elucidated.
However, such testing is not always possible given that
for most there are no standardized, commercially available8 Advances in Hematology
assays and that reactions may be related to metabolites as
opposed to more easily tested parent compounds.
As medicine advances, older drugs become obsolete and
are replaced by newer formulations. Many drugs formerly
associated with hematologic toxicities (e.g., penicillin, alpha
methyl-dopa, quinidine, gold, and chloramphenical) are no
longer in common use. However, newer drugs are found
to be associated with their own potential hematologic
toxicities (e.g., clopidogel, linezolid, ribavirin, rituximab,
and GPIIb/IIIa inhibitors). Furthermore, in addition to
classic drug-induced cytopenias, we are increasingly seeing
thrombosis as a common theme with a number of diverse
agents (e.g., heparin, COX-2 inhibitors, bevacizumab,
hormone replacement therapy, tamoxifen, erythropoietin,
thalidomide and lenalidomide). Physicians from a wide
variety of specialties need to understand the hematological
consequences of drugs and be prepared for the occurrence
and correction of these events in their patients.
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